RT Journal Article
SR Electronic
T1 Extreme γ’ fibrinogen levels in COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.20.22269321
DO 10.1101/2022.01.20.22269321
A1 Farrell, David H.
A1 Hudkins, Matthew
A1 Hamilton, Heather
A1 Underwood, Samantha J.
A1 Dewey, Elizabeth N.
A1 Kazmierczak, Diana E.
A1 Kazmierczak, Steven C.
A1 Messer, William B.
A1 Khan, Akram
A1 Schreiber, Martin A.
YR 2022
UL http://medrxiv.org/content/early/2022/01/21/2022.01.20.22269321.abstract
AB Background COVID-19 progression can be accompanied by a “cytokine storm” that leads to secondary sequelae such as thrombosis and acute respiratory distress syndrome. Several inflammatory cytokines have been associated with COVID-19 progression, but have far too much daily intra-individual variability to be useful in tracking the course of the disease. In contrast, we have shown that the inflammatory biomarker γ’ fibrinogen (γ’ Fbg) has a 6-fold lower coefficient of variability compared to other inflammatory markers such as hs-CRP. Objectives: The aims of the study were to measure γ’ Fbg in serial blood samples from COVID-19 patients at a tertiary care medical center in order to investigate its association with clinical measures of disease progression.Methods COVID-19 patients at a tertiary care medical center were retrospectively enrolled between 3/16/2020 and 8/1/2020. γ’ Fbg was measured using a commercial ELISA. Results: Our results showed that nine out of the seventeen patients with COVID-19 had extremely high levels of γ’ Fbg. γ’ Fbg levels were significantly associated with the need for ECMO and with mortality.Conclusions We found that COVID-19 patients can develop extraordinarily high levels of γ’ Fbg. The previous highest γ’ Fbg level that we are aware of was 80.3 mg/dL found in a study of 10,601 participants in the ARIC study. These results have several important clinical implications. γ’ Fbg contains a high affinity binding site for thrombin that binds to anion-binding exosite II on thrombin and protects it from inactivation by heparin. High levels of γ’ Fbg therefore provide a reservoir of heparin-resistant clot-bound thrombin when the γ’ Fbg is clotted. These findings have potential implications regarding prophylactic anticoagulation of COVID-19 patients and suggest that heparin prophylaxis may be less effective than using other anticoagulants, particularly direct thrombin inhibitors.Competing Interest StatementOHSU and David H. Farrell have a significant interest in Gamma Diagnostics, a company that may have a commercial interest in the results of this research and technology. This potential individual and institutional conflict of interest has been reviewed and managed by OHSU.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of OHSU gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsγ’ Fbgγ’ fibrinogenARDSacute respiratory distress syndromeARICAtherosclerosis Risk In Communities studyCOVID-19coronavirus disease 2019DOACdirect oral anticoagulantECMOextracorporeal membrane oxygenationELISAenzyme-linked immunosorbent assayhs-CRPhigh-sensitivity C-reactive proteinIL-6interleukin-6IRBinstitutional review boardOHSUOregon Health & Science UniversityPAR-1protease-activated receptor-1PAR-4protease-activated receptor-4Sars-CoV-2severe acute respiratory syndrome coronavirus